SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the company's SSi Mantra 3.0 surgical robotic system, according to a recent company update. This development represents a notable step in the adoption of robotic-assisted cardiac procedures in South Asia and underscores the expanding global reach of SS Innovations' technology.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The LIMA takedown is a critical step in coronary artery bypass grafting, and performing it robotically can offer enhanced precision and potentially lead to better patient outcomes. The collaboration between SS Innovations and Kings Hospital highlights a shared commitment to advancing surgical care in the region.
According to a company video describing the program's early activity, Kings Hospital has completed more than 25 robotic procedures in just three weeks. This rapid uptake demonstrates both the feasibility and the enthusiasm for robotic cardiac surgery in Sri Lanka. The successful implementation of the program could serve as a model for other hospitals in the region, potentially accelerating the adoption of robotic-assisted surgery across Southeast Asia.
SS Innovations also reported strong operational metrics. At the end of the second quarter, the company had 224 cumulative SSi Mantra installations across 12 countries. Revenue for the second quarter reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures point to rising utilization of the company's installed base and growing acceptance of its technology among surgeons worldwide.
The next major corporate milestone for SS Innovations is regulatory expansion. The company is actively pursuing U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up significant new markets and further legitimize the company's technology on a global scale. For investors and industry observers, these regulatory efforts are key indicators of the company's potential for sustained growth.
The launch of Sri Lanka's first robotic cardiac surgery program is more than a corporate achievement; it signals a broader trend toward the globalization of advanced surgical robotics. As healthcare systems in emerging markets seek to improve surgical outcomes and reduce recovery times, robotic-assisted surgery is becoming an increasingly attractive option. SS Innovations' success in Sri Lanka could encourage other hospitals in the region to invest in similar programs, ultimately benefiting patients through access to less invasive procedures.
For readers, this news matters because it illustrates how innovative medical technologies are reaching new geographies, potentially raising the standard of care. It also highlights the competitive landscape of surgical robotics, where companies like SS Innovations are challenging established players by expanding into underserved markets. As the company works toward FDA and CE mark approvals, its progress will be watched closely by healthcare providers, investors, and patients alike.
Full terms of use and disclaimers are available on the InvestorBrandNetwork website.
